HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief: Elizabeth Arden, Ronkin Part Ways; Lauder Execs Advance; More

This article was originally published in The Rose Sheet

Executive Summary

LUXE Brands and Fekkai Brands, which the former created through a joint venture earlier this year to acquire the Frederic Fekkai brand from P&G, will be led by Joel Ronkin, who has left Elizabeth Arden after 16 years of service. More people news.

You may also be interested in...



In Brief: Contamination Recall; ‘Made In America’ Questioned; More

Contract manufacturer Sensible Organics recalls Nourish Organic facial skin-care items due to potential contamination; Revlon's "Almay Simply American" marketing comes under fire for alleged deception. More news in brief.

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel